Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GVAX and Cyclophosphamide with ADT in High-risk Localized Prostate Cancer
NCT01696877Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jan 2013
- Primary completion
- Aug 2017
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of GVAX pancreatic cancer vaccine in prostate cancer (PCa), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Jan 2013; status: completed.
02
Drugs
GVAX pancreatic cancer vaccine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01696877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01696877.